NCT06439862 Study of the Quality of Life in School Aged-children With Posterior Urethral Valves
| NCT ID | NCT06439862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Quality of Life |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-08-20 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-08-20 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Posterior urethral valves (PUV) are the most common congenital obstructive lesion of the urethra, affecting from 1 per 3000 to 1 per 8000 live births. Valve ablation usually resolves the obstruction in PUV but patients still may suffer of deterioration in renal and urinary functions. Renal insufficiency is the most feared long-term complication. Up to 50 % of the patients will develop chronic kidney disease (CKD), and up to 20 % will develop end-stage renal disease (ESRD) and ultimately will require kidney transplantation. PUV is the first urological cause of ESRD. Progression towards CKD depends on febrile urinary tract infections (UTIs), severity of a vesicoureteral reflux and bladder dysfunction. Bladder dysfunction is due to an overactive and small poorly compliant bladder during infancy. Detrusor overactivity usually decreases in childhood and bladder capacity increases. The most common symptom of this bladder dysfunction is urinary incontinence. 60 % of children are continent at the age of 5 years old and 90 % at 10 years old. In case of persistent bladder dysfunction, medical treatment (anticholinergics, alpha-blockers) may be introduced, or even intermittent catheterizations. Current scientific literature has very few studies on quality of life (QoL) in patients with PUV, mostly in adult patients and very small cohorts. Men treated for PUV in childhood had a good quality of life compared to the normative population, except for sleeping, eating and sexual activity. It seemed that the more severe the urological and nephrological functions were, the lower the QoL was. Children were only asked about intermittent urinary catheterization, and family point of view has never been collected. However, QoL and long-term evolution represent the first concerns of parents-to-be in prenatal counseling, or after diagnosis in an infant with PUV. Hence, the aim of the study is to investigate the quality of life in school-aged children who had been treated for PUV in their first year of life, as measured by the Pediatric Quality of Life Inventory Version 4.0 (PedsQL 4.0).
Eligibility Criteria
Inclusion Criteria: * Male patients and their parents/relatives * Aged 6 to 17 years old * Treated for PUV in their first year of life between 2006 and 2018 * Managed in the Femme-Mère-Enfant Hospital in Lyon Exclusion Criteria: * Children with pre-existing severe cognitive and physical disability (physician's rating) from other condition * Children enable to complete QoL questionnaire due to mental or communication impairment
Contact & Investigator
BIDAULT Valeska, MD
PRINCIPAL INVESTIGATOR
Hospices Civils de Lyon
Frequently Asked Questions
Who can join the NCT06439862 clinical trial?
This trial is open to male participants only, aged 6 Years or older, up to 17 Years, studying Quality of Life. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06439862 currently recruiting?
Yes, NCT06439862 is actively recruiting participants. Contact the research team at valeska.bidault@chu-lyon.fr for enrollment information.
Where is the NCT06439862 trial being conducted?
This trial is being conducted at Bron, France.
Who is sponsoring the NCT06439862 clinical trial?
NCT06439862 is sponsored by Hospices Civils de Lyon. The principal investigator is BIDAULT Valeska, MD at Hospices Civils de Lyon. The trial plans to enroll 300 participants.